Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng et al .
Vidya Sankar ViswanathanMohammadhadi KhorramiKhalid JaziehPingfu FuNathan A PennellAnant MadabhushiPublished in: Journal for immunotherapy of cancer (2022)